Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer

Cheng, Heather H.; Plets, Melissa; Liu, Hongli; Higano, Celestia S.; Tangen, Catherine M.; Agarwal, Neeraj; Vogelzang, Nicholas J.; Hussain, Maha; Thompson, Ian M.; Tewari, Muneesh; Yu, Evan Y.

doi:10.1002/pros.23452

Cited by 29 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that exosome isolation from liquid biopsies improves the sensitivity of miRNA amplification and detection [53]. Cumulating data suggest that miRNAs have potential as diagnostic and/or prognostic biomarkers in PCa [55][56][57][58][59]. Several miRNAs have been studied in plasma and serum of mCRPC patients.…”

Section: Circulating Nucleic Acidsmentioning

confidence: 99%

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

Boerrigter¹,

Groen

Erp³

et al. 2019

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Introduction: Prostate cancer (PCa) is one of the most common malignancies in men and a major cause of cancer deaths among men worldwide. Prostate specific antigen (PSA) monitoring and histopathological examination of tumor biopsies remain gold standards in PCa diagnostics. These clinical parameters are not well suited for patient stratification, predicting and monitoring treatment response. On the other hand, liquid biopsies offer a unique opportunity to easily isolate tumor-derived material for longitudinal clinical assessment. Areas covered: In this review we focus on the clinical application of novel liquid biomarkers that have the potential to monitor and stratify patients in order to achieve better therapeutic effects and improve clinical outcomes. Enumeration and characterization of circulating tumor cells (CTCs), tumor-educated platelets, exosomes, and cell-free nucleic acids have been studied for their clinical utility in PCa diagnostics, prognostics, monitoring treatment response and guiding treatment choice. Expert opinion: Liquid biomarkers have high potential to be used for prognosis, monitoring treatment response and guiding treatment selection. Although there is a remarkable progress in PCa biomarker discovery, their clinical validation is very limited. Research should be focused on biomarker validation and the incorporation of these biomarkers in clinical practice.

show abstract

Section: Circulating Nucleic Acidsmentioning

confidence: 99%

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

Boerrigter¹,

Groen

Erp³

et al. 2019

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…The miRNA signatures are also helpful in determination of the primary site in tumors of unknown origin (22)(23)(24). Use of the miRNAs as blood-based markers has tremendous potential when used in combination with the existing PSA screening techniques for the status of the disease-cancer or not (25)(26)(27), and course of treatment (28)(29)(30)(31).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is one of the leading causes of death despite an astoundingly high survival rate for localized tumors. Though prostate specific antigen (PSA) test, performed in conjunction with digital rectal examinations, is reasonably accurate, there are major caveats requiring a thorough assessment of risks and benefits prior to conducting the test. MicroRNAs, a class of small non-coding RNAs, are stable molecules that can be detected in circulation by non-invasive methods and have gained importance in cancer prognosis and diagnosis in the recent years. Here, we investigate circulating miR-940, a miRNA known to play a role in prostate cancer progression, in both cell culture supernatants as well as patient serum and urine samples to determine the utility of miR-940 as a new molecular marker for prostate cancer detection. We found that miR-940 was significantly higher in serum from cancer patients, specifically those with clinically significant tumors (GS ≥ 7). Analysis of receiver operating characteristic curve demonstrated that miR-940 in combination with PSA had a higher area under curve value (AUC: 0.818) than the miR-940 alone (AUC: 0.75) for the diagnosis of prostate cancer. This study provides promising results suggesting the use of miR-940 for prostate cancer diagnosis.

show abstract

“…The identification of gene and miRNA biomarkers for both the early detection and prognosis of PC is a current challenge. However, currently, there are only few clinical trials with such purposes [ 99 , 100 , 101 ]. We hypothesized that gene and miRNA signatures of PC could be found by identifying sub-pathways of co-regulated genes that are targeted by specific miRNAs.…”

Section: Discussionmentioning

confidence: 99%

In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer

Cava

Bertoli

Colaprico

et al. 2018

IJMS

View full text Add to dashboard Cite

Like other cancer diseases, prostate cancer (PC) is caused by the accumulation of genetic alterations in the cells that drives malignant growth. These alterations are revealed by gene profiling and copy number alteration (CNA) analysis. Moreover, recent evidence suggests that also microRNAs have an important role in PC development. Despite efforts to profile PC, the alterations (gene, CNA, and miRNA) and biological processes that correlate with disease development and progression remain partially elusive. Many gene signatures proposed as diagnostic or prognostic tools in cancer poorly overlap. The identification of co-expressed genes, that are functionally related, can identify a core network of genes associated with PC with a better reproducibility. By combining different approaches, including the integration of mRNA expression profiles, CNAs, and miRNA expression levels, we identified a gene signature of four genes overlapping with other published gene signatures and able to distinguish, in silico, high Gleason-scored PC from normal human tissue, which was further enriched to 19 genes by gene co-expression analysis. From the analysis of miRNAs possibly regulating this network, we found that hsa-miR-153 was highly connected to the genes in the network. Our results identify a four-gene signature with diagnostic and prognostic value in PC and suggest an interesting gene network that could play a key regulatory role in PC development and progression. Furthermore, hsa-miR-153, controlling this network, could be a potential biomarker for theranostics in high Gleason-scored PC.

show abstract

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer

Cited by 29 publications

References 28 publications

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer

In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer

Contact Info

Product

Resources

About